The Autoimmune Encephalitis (Post-Infectious) drugs in development market research report provides comprehensive information on the therapeutics under development for Autoimmune Encephalitis (Post-Infectious), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Autoimmune Encephalitis (Post-Infectious). Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Autoimmune Encephalitis (Post-Infectious) and features dormant and discontinued products.
GlobalData tracks eight drugs in development for Autoimmune Encephalitis (Post-Infectious) by eight companies/universities/institutes. The top development phase for Autoimmune Encephalitis (Post-Infectious) is preclinical with three drugs in that stage. The Autoimmune Encephalitis (Post-Infectious) pipeline has eight drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Autoimmune Encephalitis (Post-Infectious) pipeline products market are: F. Hoffmann-La Roche, UCB and Nihon Pharmaceuticals.
The key targets in the Autoimmune Encephalitis (Post-Infectious) pipeline products market include B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1), Glutamate Receptor Ionotropic NMDA 1 (Glutamate [NMDA] Receptor Subunit Zeta 1 or N Methyl D Aspartate Receptor Subunit NR1 or GRIN1), and IgG Receptor FcRn Large Subunit p51 (IgG Fc Fragment Receptor Transporter Alpha Chain or Neonatal Fc Receptor or FCGRT or FCRN).
The key mechanisms of action in the Autoimmune Encephalitis (Post-Infectious) pipeline product include B Lymphocyte Antigen CD20 (B Lymphocyte Surface Antigen B1 or Bp35 or Leukocyte Surface Antigen Leu 16 or Membrane Spanning 4 Domains Subfamily A Member 1 or CD20 or MS4A1) Inhibitor with one drug in Phase II. The Autoimmune Encephalitis (Post-Infectious) pipeline products include three routes of administration with the top ROA being Intravenous and four key molecule types in the Autoimmune Encephalitis (Post-Infectious) pipeline products market including Monoclonal Antibody, and Small Molecule.
Autoimmune Encephalitis (Post-Infectious) overview
Autoimmune encephalitis refers to acute to subacute, progressive inflammation of the brain associated with antibodies against neuronal cell surface and synaptic protein, most commonly being anti – NMDA receptor encephalitis. It is thought to be an autoimmune process with an exaggerated response to a neuronal self-antigen. Unlike paraneoplastic encephalitis, which is a T-cell mediated response, antibodies in AIE are intrinsically pathogenic.
For a complete picture of Autoimmune Encephalitis (Post-Infectious)’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
